Kimberly-Clark to Acquire Kenvue
Kimberly-Clark has announced a cash and stock acquisition of Kenvue, the maker of Tylenol, valued at approximately $48.7 billion.
Upon completion, Kimberly-Clark shareholders will own about 54% of the combined company, while Kenvue shareholders will hold 46%.
The Big Picture
The merger brings together a broad array of popular consumer brands, including Kenvue’s Tylenol, Listerine, and Band-Aid alongside Kimberly-Clark’s Cottonelle, Huggies, and Kleenex.
Key Details
- The takeover is one of the largest corporate deals announced in 2025.
- Kimberly-Clark Chairman and CEO Mike Hsu will lead the merged company.
- Three Kenvue board members will join Kimberly-Clark’s board upon closing.
We will serve billions of consumers across every stage of life. - Mike Hsu, Kimberly-Clark Chairman and CEO
Author's summary: Kimberly-Clark buys Kenvue for $48.7 billion.